These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 28422431)

  • 1. Effect of Empagliflozin on Tacrolimus-Induced Pancreas Islet Dysfunction and Renal Injury.
    Jin J; Jin L; Luo K; Lim SW; Chung BH; Yang CW
    Am J Transplant; 2017 Oct; 17(10):2601-2616. PubMed ID: 28422431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of dual inhibition of DPP4 and SGLT2 on tacrolimus-induced diabetes mellitus and nephrotoxicity in a rat model.
    Ko EJ; Shin YJ; Cui S; Lim SW; Chung BH; Yang CW
    Am J Transplant; 2022 Jun; 22(6):1537-1549. PubMed ID: 35294797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Conversion to CTLA4Ig on Tacrolimus-Induced Diabetic Rats.
    Jin L; Lim SW; Jin J; Luo K; Ko EJ; Chung BH; Lin HL; Yang CW
    Transplantation; 2018 Apr; 102(4):e137-e146. PubMed ID: 29319618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of metformin on hyperglycemia in an experimental model of tacrolimus- and sirolimus-induced diabetic rats.
    Jin J; Lim SW; Jin L; Yu JH; Kim HS; Chung BH; Yang CW
    Korean J Intern Med; 2017 Mar; 32(2):314-322. PubMed ID: 27688296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes.
    Cheng ST; Chen L; Li SY; Mayoux E; Leung PS
    PLoS One; 2016; 11(1):e0147391. PubMed ID: 26807719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deciphering Tacrolimus-Induced Toxicity in Pancreatic β Cells.
    Triñanes J; Rodriguez-Rodriguez AE; Brito-Casillas Y; Wagner A; De Vries APJ; Cuesto G; Acebes A; Salido E; Torres A; Porrini E
    Am J Transplant; 2017 Nov; 17(11):2829-2840. PubMed ID: 28432716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase IV inhibitor MK-0626 attenuates pancreatic islet injury in tacrolimus-induced diabetic rats.
    Jin L; Lim SW; Doh KC; Piao SG; Jin J; Heo SB; Chung BH; Yang CW
    PLoS One; 2014; 9(6):e100798. PubMed ID: 24959755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).
    Domon A; Katayama K; Sato T; Tochigi Y; Tazaki H; Suzuki H
    PLoS One; 2021; 16(5):e0251135. PubMed ID: 33945582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.
    Nagata T; Fukuzawa T; Takeda M; Fukazawa M; Mori T; Nihei T; Honda K; Suzuki Y; Kawabe Y
    Br J Pharmacol; 2013 Oct; 170(3):519-31. PubMed ID: 23751087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis.
    Ojima A; Matsui T; Nishino Y; Nakamura N; Yamagishi S
    Horm Metab Res; 2015 Aug; 47(9):686-92. PubMed ID: 25611208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity.
    Oelze M; Kröller-Schön S; Welschof P; Jansen T; Hausding M; Mikhed Y; Stamm P; Mader M; Zinßius E; Agdauletova S; Gottschlich A; Steven S; Schulz E; Bottari SP; Mayoux E; Münzel T; Daiber A
    PLoS One; 2014; 9(11):e112394. PubMed ID: 25402275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus.
    Luippold G; Klein T; Mark M; Grempler R
    Diabetes Obes Metab; 2012 Jul; 14(7):601-7. PubMed ID: 22268612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulatory effect of empagliflozin on cellular parameters of endocrine pancreas in experimental pre-diabetes.
    Abdel-Hamid AAM; Firgany AEL
    Ann Anat; 2019 Jul; 224():153-160. PubMed ID: 31108190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the effect of canagliflozin on renal glucose reabsorption and progression of hyperglycemia in zucker diabetic Fatty rats.
    Kuriyama C; Xu JZ; Lee SP; Qi J; Kimata H; Kakimoto T; Nakayama K; Watanabe Y; Taniuchi N; Hikida K; Matsushita Y; Arakawa K; Saito A; Ueta K; Shiotani M
    J Pharmacol Exp Ther; 2014 Nov; 351(2):423-31. PubMed ID: 25216746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Treatment with Empagliflozin and GABA Improves
    Daems C; Welsch S; Boughaleb H; Vanderroost J; Robert A; Sokal E; Lysy PA
    J Diabetes Res; 2019; 2019():2813489. PubMed ID: 31467926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2-i improves markers of islet endothelial cell function in db/db diabetic mice.
    Hogan MF; Hackney DJ; Aplin AC; Mundinger TO; Larmore MJ; Castillo JJ; Esser N; Zraika S; Hull RL
    J Endocrinol; 2021 Feb; 248(2):95-106. PubMed ID: 33337344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective Effect of Ipragliflozin on Pancreatic Islet Cells in Obese Type 2 Diabetic db/db Mice.
    Takasu T; Takakura S
    Biol Pharm Bull; 2018; 41(5):761-769. PubMed ID: 29709913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.
    Lin B; Koibuchi N; Hasegawa Y; Sueta D; Toyama K; Uekawa K; Ma M; Nakagawa T; Kusaka H; Kim-Mitsuyama S
    Cardiovasc Diabetol; 2014 Oct; 13():148. PubMed ID: 25344694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined treatment of tacrolimus and everolimus increases oxidative stress by pharmacological interactions.
    Piao SG; Lim SW; Doh KC; Jin L; Heo SB; Zheng YF; Bae SK; Chung BH; Li C; Yang CW
    Transplantation; 2014 Jul; 98(1):22-8. PubMed ID: 24825522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro.
    Baer PC; Koch B; Freitag J; Schubert R; Geiger H
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.